Latest Conference Articles

Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

42nd Annual Meeting in Stockholm, the Venice of the North

A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

Presenters from around the world converge on the Pacific Northwest to highlight innovation.

The 2024 event was held in Seattle, Washington, from May 5 through May 9. Members of the Ophthalmology Times team attended and interviewed several researchers and industry professionals, highlighting news from the meeting.

This podcast features engaging commentary from experts in the clinical management of glaucoma. These experts share information about traditional and newer therapies for glaucoma, including topical drops, sustained drug delivery options, and minimally invasive glaucoma surgery. They discuss safety and efficacy data with an emphasis on appropriate patient selection, as well as key take-home points and practice pearls.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

ARVO attendees took a deep dive into trends and explored the near future of vision science

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.

Arshad M. Khanani, MD, MA, shares what attendees and the retina community can expect from the Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.

Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.

Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.